MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Начало・Списък с акции・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

17.28 -1.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.88

Максимум

17.6

Ключови измерители
By Trading Economics
Приходи	21M -36M
Продажби	16M 213M
EPS	-0.29
Марж на печалбата	-17.105
Служители	705
EBITDA	20M -24M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+136.94% upside

Дивиденти
By Dow Jones
Следващи печалби	1.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 2.3B
Предишно отваряне	18.76
Предишно затваряне	17.28

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Intel, AppFolio

24.04.2025 г., 23:51 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24.04.2025 г., 23:37 ч. UTC

Топ новини

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24.04.2025 г., 23:36 ч. UTC

Топ новини

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24.04.2025 г., 23:13 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- Update

24.04.2025 г., 23:09 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24.04.2025 г., 22:51 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 22:48 ч. UTC

Топ новини

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24.04.2025 г., 22:47 ч. UTC

Пазарно говорене

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24.04.2025 г., 22:38 ч. UTC

Пазарно говорене

Печалби

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24.04.2025 г., 22:24 ч. UTC

Пазарно говорене

Печалби

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24.04.2025 г., 22:23 ч. UTC

Печалби

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24.04.2025 г., 22:09 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24.04.2025 г., 22:00 ч. UTC

Пазарно говорене

Печалби

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24.04.2025 г., 21:39 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24.04.2025 г., 21:23 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24.04.2025 г., 21:04 ч. UTC

Печалби

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24.04.2025 г., 21:02 ч. UTC

Печалби

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

136.94% нагоре

12-месечна прогноза

Среден 41.56 USD 136.94%

Висок 75 USD

Нисък 21 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Apellis Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.